Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Novartis

5 stories about Novartis

Good for health, great for the economy: collaborations between pharmaceutical companies and the healthcare system in Israel
07.02.23|Sponsored ContentMore countries are discovering the economic and medical benefits that come with collaboration between pharmaceutical companies and healthcare systems. This collaborative model has already been successfully implemented by the Swiss company Novartis and the National Healthcare System (NHS) in England. The benefits include improved treatment of sclerotic cardiovascular diseases and higher economic efficiency on a national level. Is Israel next in line for a healthcare revolution?
Ayala Pharmaceuticals Raises $30 Million
29.05.19|Adi PickThe Israel-based company intends to use the new round of funding to advance the clinical development of its anti-cancer product
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
24.12.18|Lilach BaumerThe investment is part of a licensing option agreement signed between the two companies
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18|Lilach BaumerNovartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17|Lilach BaumerThe Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor

About CTech Terms of Use Privacy Policy

Back to Top